LPX-IO

N/A

Report date: 2023/12/26 17:50:47
NME

Base Information

Drug NameLPX-IO
Drug Alias NameLPX-IO
ClassificationOther
Mechanisms of ActionT-cell immunoglobulin and mucin domain-containing protein 4 antagonistsHepatitis A virus cellular receptor 2 antagonists
TargetsT-cell immunoglobulin and mucin domain-containing protein 4Hepatitis A virus cellular receptor 2
Therapy Area/IndicationsMelanomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLAPIX Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLAPIX Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMelanomaLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A